The future of CFTR modulating therapies for cystic fibrosis

Current Opinion in Pulmonary Medicine

Volumn 21, Issue 6, 2015, Pages 579-584

  Davies, Jane C ^a  

^a ROYAL BROMPTON AND HAREFIELD NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

Corrector; cystic fibrosis transmembrane conductance regulator; potentiator; read Through

Indexed keywords

CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR; IVACAFTOR;

CLINICAL RESEARCH; CYSTIC FIBROSIS; DISEASE COURSE; DRUG USE; FOLLOW UP; GENE MUTATION; HUMAN; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PROTEIN FUNCTION; REVIEW; MUTATION; PATHOPHYSIOLOGY; PERSONALIZED MEDICINE;

CYSTIC FIBROSIS; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR; HUMANS; MUTATION; PRECISION MEDICINE;

EID: 84942412001     PISSN: 10705287     EISSN: 15316971     Source Type: Journal    
DOI: 10.1097/MCP.0000000000000211     Document Type: Review

References (39)

1. Wainwright BJ, Scambler PJ, Schmidtke J, et al. Localization of cystic fibrosis locus to human chromosome 7cen-q22. Nature 1985; 318:384-385.
2. Rommens JM, Iannuzzi MC, Kerem B, et al. Identification of the cystic fibrosis gene: chromosome walking and jumping. Science (New York, NY) 1989; 245:1059-1065.
3. Riordan JR, Rommens JM, Kerem B, et al. Identification of the cystic fibrosis gene: cloning and characterization of complementary DNA. Science (New York, NY) 1989; 245:1066-1073.
4. Matsui H, Grubb BR, Tarran R, et al. Evidence for periciliary liquid layer depletion, not abnormal ion composition, in the pathogenesis of cystic fibrosis airways disease. Cell 1998; 95:1005-1015.
5. Pezzulo AA, Tang XX, Hoegger MJ, et al. Reduced airway surface pH impairs bacterial killing in the porcine cystic fibrosis lung. Nature 2012; 487:109-113.
6. CFTR2 (Internet). Available from: http://www.cftr2.com. Accessed July 2015.
7. UK Cystic Fibrosis Registry Annual Data Report 2013 (Internet). Available from: http://www.cysticfibrosis.org.uk/media/598466/annual-data-report-2013-jul14.pdf. Accessed July 2015.
8. Wilschanski M, Miller LL, Shoseyov D, et al. Chronic ataluren (PTC124) treatment of nonsense mutation cystic fibrosis. Eur Respir J 2011; 38:59-69.
9. Wilschanski M, Kerem E. New drugs for cystic fibrosis. Expert Opin Investig Drugs 2011; 20:1285-1292.
10. Kerem E, Konstan MW, De Boeck K, et al. Ataluren for the treatment of nonsense-mutation cystic fibrosis: A randomised, double-blind, placebo-controlled phase 3 trial. Lancet Respir Med 2014; 2:539-547.
11. Ramsey BW, Davies J, McElvaney NG, et al. A CFTR potentiator in patients with cystic fibrosis and the GLY551ASP mutation. N Engl J Med 2011; 365:1663-1672.
12. Davies JC, Wainwright CE, Canny GJ, et al. Efficacy and safety of ivacaftor in patients aged 6 to 11 years with cystic fibrosis with a G551D mutation. Am J Respir Crit Care Med 2013; 187:1219-1225.
13. Yu H, Burton B, Huang CJ, et al. Ivacaftor potentiation of multiple CFTR channels with gating mutations. J Cyst Fibros 2012; 11:237-245.
14. Davies J, Sheridan H, Bell N, et al. Assessment of clinical response to ivacaftor with lung clearance index in cystic fibrosis patients with a GLY551ASP-CFTR mutation and preserved spirometry: A randomised controlled trial. Lancet Respir Med 2013; 1:630-638.
15. Barry PJ, Plant BJ, Nair A, et al. Effects of ivacaftor in patients with cystic fibrosis who carry the GLY551ASP mutation and have severe lung disease. Chest 2014; 146:152-158.
16. Rowe SM, Heltshe SL, Gonska T, et al. Clinical mechanism of the cystic fibrosis transmembrane conductance regulator potentiator ivacaftor in GLY551ASP-mediated cystic fibrosis. Am J Respir Crit Care Med 2014; 190:175-184.
17. Heltshe SL, Mayer-Hamblett N, Burns JL, et al. Pseudomonas aeruginosa in cystic fibrosis patients with GLY551ASP-CFTR treated with ivacaftor. Clin Infect Dis 2015; 60:703-712.
18. Rowe SM. Boyle MP. Combination of correctors and potentiators for F508Del CFTR. Pediatr Pulmonol Suppl 2011; 46:180(Summary S15.3).
19. Brown CR, Hong-Brown LQ, Biwersi J, et al. Chemical chaperones correct the mutant phenotype of the delta F508 cystic fibrosis transmembrane conductance regulator protein. Cell Stress Chaperones 1996; 1:117-125.
20. Sato S, Ward CL, Krouse ME, et al. Glycerol reverses the misfolding phenotype of the most common cystic fibrosis mutation. J Biol Chem 1996; 271:635-638.
21. Van Goor F, Hadida S, Grootenhuis PD, et al. Correction of the F508del-CFTR protein processing defect in vitro by the investigational drug VX-809. Proc Natl Acad Sci U S A 2011; 108:18843-18848.
22. Clancy JP, Rowe SM, Accurso FJ, et al. Results of a phase IIa study of VX-809, an investigational CFTR corrector compound, in subjects with cystic fibrosis homozygous for the F508del-CFTR mutation. Thorax 2012; 67:12-18.
23. Wainwright CE, Elborn JS, Ramsey BW, et al. Lumacaftor-ivacaftor in patients with cystic fibrosis homozygous for Phe508del CFTR. N Engl J Med 2015; 373:220-231.
24. Boyle MP, Bell SC, Konstan MW, et al. A CFTR corrector (lumacaftor) and a CFTR potentiator (ivacaftor) for treatment of patients with cystic fibrosis who have a phe508del CFTR mutation: A phase 2 randomised controlled trial. Lancet Respir Med 2014; 2:527-538.
25. A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of VX-661 in Combination With Ivacaftor; NCT02347657 (Internet). Available from: https://clinicaltrials.gov/. Accessed July 2015.
26. Phase 3 Study of VX-661 in Combination With Ivacaftor in Subjects Aged 12 Years and Older With Cystic Fibrosis, Who Have One F508del-CFTR Mutation and a Second Mutation That Has Been Demonstrated to be Clinically Responsive to Ivacaftor, NCT02412111 (Internet). Available from: https://clinicaltrials.gov/. Accessed July 2015.
27. A Phase 3 Study to Evaluate the Efficacy and Safety of Ivacaftor and VX-661 in Combination With Ivacaftor in Subjects Aged 12 Years and Older With Cystic Fibrosis, Heterozygous for the F508del-CFTR Mutation, NCT02392234 (Internet). Available from: https://clinicaltrials.gov/. Accessed July 2015.
28. Safety, Tolerability, Pharmacokinetics, and Preliminary Pharmacodynamics of QBW251 in Healthy Subjects and Cystic Fibrosis Patients, NCT02190604 (Internet). Available from: https://clinicaltrials.gov/. Accessed July 2015.
29. Study of N91115 in Patients With Cystic Fibrosis Homozygous F508del-CFTR Mutation (SNO4), NCT02275936 (Internet). Available from: https://clinicaltrials.gov/. Accessed July 2015.
30. Early Signs of Efficacy Study With Riociguat in Adult Homozygous Delta F508 Cystic Fibrosis Patients, NCT02170025 (Internet). Available from: https://clinicaltrials.gov/. Accessed July 2015.
31. Safety and Pharmacokinetic Study of N6022 in Subjects With Cystic Fibrosis Homozygous for the F508del-CFTR Mutation (SNO-1), NCT01746784 (Internet). Available from: https://clinicaltrials.gov/. Accessed July 2015.
32. Balch WE, Roth DM, Hutt DM. Emergent properties of proteostasis in managing cystic fibrosis. Cold Spring Harb Perspect Biol 2011; 3; a004499.
33. Ryan NJ. Ataluren: first global approval. Drugs 2014; 74:1709-1714.
34. Dekkers R, Vijftigschild LA, VonkAM, et al.A bioassay using intestinal organoids to measure CFTR modulators in human plasma. J Cyst Fibros 2015; 14:178-181.
35. Guyatt G, Sackett D, Taylor DW, et al. Determining optimal therapy: randomized trials in individual patients. N Engl J Med 1986; 314:889-892.
36. Alton EW, Armstrong DK, Ashby D, et al.RepeatednebulisationofnonviralCFTR genetherapyinpatientswithcysticfibrosis:arandomised, double-blind, placebocontrolled, phase 2b trial. Lancet Respir Med 2015. [Epub ahead of print]
37. Conese M, Piro D, Carbone A, et al. Hematopoietic and mesenchymal stem cells for the treatment of chronic respiratory diseases: role of plasticity and heterogeneity. ScientificWorldJournal 2014; 2014: 859817.
38. Montiel-Gonzalez MF, Vallecillo-Viejo I, Yudowski GA, Rosenthal JJ. Correction of mutations within the cystic fibrosis transmembrane conductance regulator by site-directed RNA editing. Proc Natl Acad Sci U S A 2013; 110:18285-18290.
39. European Health Forum Workshop Report: European Commission Health Research Directorate. Available from: https://ec.europa.eu/research/health/pdf/13th-european-health-forum-workshop-report-en.pdf. Accessed 28 July 2015.